ATE486583T1 - Pharmazeutische zusammensetzung enthaltend anastrozol - Google Patents

Pharmazeutische zusammensetzung enthaltend anastrozol

Info

Publication number
ATE486583T1
ATE486583T1 AT06779229T AT06779229T ATE486583T1 AT E486583 T1 ATE486583 T1 AT E486583T1 AT 06779229 T AT06779229 T AT 06779229T AT 06779229 T AT06779229 T AT 06779229T AT E486583 T1 ATE486583 T1 AT E486583T1
Authority
AT
Austria
Prior art keywords
formulations
anastrozole
pharmaceutical composition
composition containing
treatment
Prior art date
Application number
AT06779229T
Other languages
English (en)
Inventor
Paul Gellert
Balvinder Matharu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE486583T1 publication Critical patent/ATE486583T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06779229T 2005-08-31 2006-08-29 Pharmazeutische zusammensetzung enthaltend anastrozol ATE486583T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517674.8A GB0517674D0 (en) 2005-08-31 2005-08-31 Formulation
PCT/GB2006/003199 WO2007026138A1 (en) 2005-08-31 2006-08-29 Formulation

Publications (1)

Publication Number Publication Date
ATE486583T1 true ATE486583T1 (de) 2010-11-15

Family

ID=35198617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06779229T ATE486583T1 (de) 2005-08-31 2006-08-29 Pharmazeutische zusammensetzung enthaltend anastrozol

Country Status (9)

Country Link
US (1) US20080248077A1 (de)
EP (1) EP1924242B1 (de)
JP (1) JP2009506100A (de)
CN (1) CN101296685A (de)
AT (1) ATE486583T1 (de)
DE (1) DE602006018027D1 (de)
ES (1) ES2354197T3 (de)
GB (1) GB0517674D0 (de)
WO (1) WO2007026138A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2037884A2 (de) * 2006-06-22 2009-03-25 Novartis AG Aromatasehemmerformulierungen mit verzögerter freisetzung
US8691301B2 (en) * 2008-06-30 2014-04-08 Kimberly-Clark Worldwide, Inc. Surfactant gas pressurized liquid composition and method and package for delivering
US20100144687A1 (en) * 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
ES2390439B1 (es) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
CN106580868B (zh) * 2017-01-24 2020-06-16 广州帝奇医药技术有限公司 一种植入剂及其制备方法
WO2022256521A1 (en) * 2021-06-02 2022-12-08 Board Of Regents, The University Of Texas System Drug-eluting tubes for improved patient care
TW202308595A (zh) * 2021-08-13 2023-03-01 大陸商江西濟民可信集團有限公司 一種微球懸液、微粒製劑及其製備方法
CN116803378B (zh) * 2023-08-24 2023-11-17 北京福元医药股份有限公司 一种格列齐特缓释片剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6855331B2 (en) * 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
EP0817619A4 (de) * 1996-01-24 1999-02-03 Us Army Neue poly-(lactid/glycolid)-mikrosphären mit verzögerter freisetzung ohne initialstoss
JP2002068982A (ja) * 2000-06-14 2002-03-08 Takeda Chem Ind Ltd 徐放性組成物
US20040023987A1 (en) * 2000-06-14 2004-02-05 Yoshio Hata Sustained release compositions
EP1356809A4 (de) * 2000-12-28 2008-05-14 Takeda Pharmaceutical Retardzubereitungen
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents

Also Published As

Publication number Publication date
JP2009506100A (ja) 2009-02-12
ES2354197T3 (es) 2011-03-10
GB0517674D0 (en) 2005-10-05
WO2007026138A1 (en) 2007-03-08
DE602006018027D1 (de) 2010-12-16
CN101296685A (zh) 2008-10-29
EP1924242B1 (de) 2010-11-03
US20080248077A1 (en) 2008-10-09
EP1924242A1 (de) 2008-05-28

Similar Documents

Publication Publication Date Title
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
CY1120720T1 (el) Υπομοναδα απομονωσης και σχετικες συνθεσεις και μεθοδοι
CY1120782T1 (el) Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
MY167123A (en) Conveniently implantable sustained release drug compositions
SG152240A1 (en) Pharmaceutical compositions comprising an amphiphilic starch
EP1824442A4 (de) Pharmazeutische und therapeutische zusammensetzungen aus der garcinia-mangostana-l-pflanze
RU2011115406A (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
CY1111713T1 (el) Συνθεση δισκιου εκτεταμενης απελευθερωσεως περιεχουσα πραμιπεξολη ή ενα φαρμακευτικα αποδεκτο αλας της, μεθοδος παραγωγης της και χρηση τους
ATE353888T1 (de) Chinazolinderivate
EA201070657A1 (ru) Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
CY1113482T1 (el) Αναστολεις υποδοχεα σιγμα
ATE540984T1 (de) Blockcopolymere aus polycaprolacton und poly (propylenfumarat)
CY1110293T1 (el) Μικροσωματιδια που περιλαμβανουν αναλογα σωματοστατινης
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
TW200515919A (en) Bioerodible sustained release drug delivery systems
SE0401970D0 (sv) Novel compounds
ATE481088T1 (de) Embolisierung unter verwendung von poly-4- hydroxybutyrat-partikeln
MX2010000965A (es) Productos de farmaco de interferon de liberacion controlada y tratamiento de la infeccion del virus de hepatitis c usando los mismos.
DE602006018027D1 (de) Pharmazeutische zusammensetzung enthaltend anastrozol
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
WO2007026145A8 (en) Prolonged release formulations comprising anastrozole
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
DE60305438D1 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties